Literature DB >> 32526788

The NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.

Jana Knorr1, Alexander Wree1,2, Frank Tacke1, Ariel E Feldstein2.   

Abstract

Nonalcoholic steatohepatitis (NASH) and alcoholic hepatitis (ASH) are advanced forms of fatty liver diseases that are associated with a high morbidity and mortality worldwide. Patients with ASH or NASH are more susceptible to the progression of fibrosis and cirrhosis up to the development of hepatocellular carcinoma. Currently, there are limited medical therapies available. Accompanied by the asymptomatic disease progression, the demand for liver transplants is high. This review provides an overview about the growing evidence for a central role of NLR family pyrin domain containing 3 (NLRP3) inflammasome, a multiprotein complex that acts as a central driver of inflammation via activation of caspase 1, maturation and release of pro-inflammatory cytokines including interleukin-1β, and trigger of inflammatory pyroptotic cell death in both NASH and ASH. We also discuss potential therapeutic approaches targeting NLRP3 inflammasome and related upstream and downstream pathways to develop prognostic biomarkers and medical treatments for both liver diseases. Thieme. All rights reserved.

Entities:  

Year:  2020        PMID: 32526788     DOI: 10.1055/s-0040-1708540

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  18 in total

Review 1.  Mitochondria and the NLRP3 Inflammasome in Alcoholic and Nonalcoholic Steatohepatitis.

Authors:  Sandra Torres; Paula Segalés; Carmen García-Ruiz; José C Fernández-Checa
Journal:  Cells       Date:  2022-04-27       Impact factor: 7.666

2.  Neutrophil extracellular traps enriched with IL-1β and IL-17A participate in the hepatic inflammatory process of patients with non-alcoholic steatohepatitis.

Authors:  Stella Arelaki; Triantafyllia Koletsa; Emmanuil Sinakos; Vasileios Papadopoulos; Konstantinos Arvanitakis; Panagiotis Skendros; Evangelos Akriviadis; Konstantinos Ritis; Georgios Germanidis; Prodromos Hytiroglou
Journal:  Virchows Arch       Date:  2022-05-03       Impact factor: 4.535

3.  Signal Transduction and Molecular Regulation in Fatty Liver Disease.

Authors:  Xiaocheng Charlie Dong; Kushan Chowdhury; Menghao Huang; Hyeong Geug Kim
Journal:  Antioxid Redox Signal       Date:  2021-06-03       Impact factor: 7.468

Review 4.  Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease.

Authors:  Joeri Lambrecht; Frank Tacke
Journal:  Front Immunol       Date:  2021-02-09       Impact factor: 7.561

Review 5.  NLRP3 Inflammasome Pharmacological Inhibitors in Glycyrrhiza for NLRP3-Driven Diseases Treatment: Extinguishing the Fire of Inflammation.

Authors:  Zhilei Wang; Guang Xu; Zhiyong Li; Xiaohe Xiao; Jianyuan Tang; Zhaofang Bai
Journal:  J Inflamm Res       Date:  2022-01-19

Review 6.  Liver Fibrosis-From Mechanisms of Injury to Modulation of Disease.

Authors:  Christian Liedtke; Yulia A Nevzorova; Tom Luedde; Henning Zimmermann; Daniela Kroy; Pavel Strnad; Marie-Luise Berres; Jürgen Bernhagen; Frank Tacke; Jacob Nattermann; Ulrich Spengler; Tilman Sauerbruch; Alexander Wree; Zeinab Abdullah; René H Tolba; Jonel Trebicka; Twan Lammers; Christian Trautwein; Ralf Weiskirchen
Journal:  Front Med (Lausanne)       Date:  2022-01-11

Review 7.  The NLRP3 Inflammasome: Relevance in Solid Organ Transplantation.

Authors:  Ryan M Burke; Bethany L Dale; Shamik Dholakia
Journal:  Int J Mol Sci       Date:  2021-10-03       Impact factor: 5.923

8.  Gut microbial trimethylamine is elevated in alcohol-associated hepatitis and contributes to ethanol-induced liver injury in mice.

Authors:  Robert N Helsley; Tatsunori Miyata; Anagha Kadam; Venkateshwari Varadharajan; Naseer Sangwan; Emily C Huang; Rakhee Banerjee; Amanda L Brown; Kevin K Fung; William J Massey; Chase Neumann; Danny Orabi; Lucas J Osborn; Rebecca C Schugar; Megan R McMullen; Annette Bellar; Kyle L Poulsen; Adam Kim; Vai Pathak; Marko Mrdjen; James T Anderson; Belinda Willard; Craig J McClain; Mack Mitchell; Arthur J McCullough; Svetlana Radaeva; Bruce Barton; Gyongyi Szabo; Srinivasan Dasarathy; Jose Carlos Garcia-Garcia; Daniel M Rotroff; Daniela S Allende; Zeneng Wang; Stanley L Hazen; Laura E Nagy; Jonathan Mark Brown
Journal:  Elife       Date:  2022-01-27       Impact factor: 8.713

9.  Macrophages Modulate Hepatic Injury Involving NLRP3 Inflammasome: The Example of Efavirenz.

Authors:  Fernando Alegre; Alberto Martí-Rodrigo; Miriam Polo; Dolores Ortiz-Masiá; Celia Bañuls; Marcello Pinti; Ángeles Álvarez; Nadezda Apostolova; Juan V Esplugues; Ana Blas-García
Journal:  Biomedicines       Date:  2022-01-05

Review 10.  Liver Injury and the Macrophage Issue: Molecular and Mechanistic Facts and Their Clinical Relevance.

Authors:  Siyer Roohani; Frank Tacke
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.